Working... Menu
Trial record 6 of 7 for:    "Neuroendocrine Carcinoma" | "Protein Kinase Inhibitors"

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02315625
Recruitment Status : Completed
First Posted : December 12, 2014
Last Update Posted : August 8, 2019
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 22, 2019
  Actual Study Completion Date : May 22, 2019
Publications automatically indexed to this study by Identifier (NCT Number):